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Abstract: Ocular surface disease (OSD) is common among glaucoma patients. Clinical 
  assessment of OSD can be challenging. This review focuses on some of the limitations relating 
to both subjective and objective measures of OSD, including dry eye. A survey of the literature 
was conducted to identify the caveats associated with different methods of assessing OSD. The 
effect of preservatives on the ocular surface, with respect to glaucoma patients in particular, 
was also reviewed. Objective methods for assessing ocular surface health and disease include 
the Schirmer test, tear break-up time, fluorescein turnover, corneal and conjunctival staining, 
tear osmolarity, and vital dyes. These measures all have limitations in terms of their ability to 
grade the severity of OSD. Previous studies using the OSD Index showed a mild-to-moderate 
correlation to dry eye disease severity. Other scoring systems for dry eye have shown a 
  relationship to patient symptom scores or quality of life. Due to the challenges clinicians face 
concerning both subjective and objective ocular surface health assessments, discerning clinical 
improvement in ocular surface disease can be a challenge. Further research is needed in order 
to optimize existing clinical methods and/or identify alternative techniques for assessing OSD 
in the glaucoma population.
Keywords: dry eye, glaucoma, ocular surface disease, ocular surface disease index,   preservatives, 
tear break-up time
Glaucoma and ocular surface disease (OSD)
Glaucoma is an optic neuropathy that is most often associated with elevated   intraocular 
pressure (IOP). The most widely prescribed therapies are topical ocular drops. 
  Prostaglandin analog (PGA) and beta-blockers are typically the initial medications 
of choice.1
Animal and human tissue studies have shown that pathologic changes to the   ocular 
surface, conjunctiva, and trabecular meshwork can occur as a result of long-term 
exposure to preservatives in the topical medication formulation.2 The contribution of 
the active ingredients to these adverse effects cannot be ruled out. For example, even 
nonpreserved IOP-lowering medications, such as timolol, can increase the expression 
of immunoinflammatory markers and cytokines (human leukocyte antigen-DR region 
[HLA-DR], interleukin [IL]-6, and IL-8) in the conjunctival epithelium of glaucoma 
patients.3 Glaucoma patients often take multiple IOP-lowering drops in order to 
adequately control their IOP. Therapeutic regimens with multiple medications can 
increase patients’ potential exposure to preservatives even further.
Rossi et al investigated the presence of dry eye syndrome in 61 patients with ocular 
hypertension or glaucoma taking one to three drops of topical IOP-lowering   medications 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1575
REVIEw
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/OPTH.S24410Clinical Ophthalmology 2011:5
per day and 20 patients not taking   medications (control 
group).4 Dry eye syndrome was defined as   concomitant 
reduced tear break-up time (TBUT) and punctate keratitis. 
Approximately 40% of those taking two or three drops per 
day had dry eye syndrome, compared with 11% of those tak-
ing one drop per day and 5% of the control group. The OSD 
Index (OSDI) questionnaire, which will be discussed in more 
detail later, was used in this study. Moderate-to-severe OSDI 
scores were observed for approximately 30% of glaucoma 
patients taking two or more drops per day. Because many 
IOP-lowering medications contain benzalkonium chloride 
(BAK), patients can be exposed to a considerable “BAK 
load” over their lifetimes.
Recent studies have examined the prevalence of OSD 
in glaucoma and ocular hypertensive patients. Leung et al 
conducted a study on 101 glaucoma patients in order to 
ascertain the prevalence of OSD.5 A majority of patients 
(59%) in this study reported symptoms of dry eye (via the 
OSDI). Schirmer tests showed 61% of the patients had a 
decrease in tear production. Positive results for corneal and 
conjunctival lissamine green staining were found in about 
22% of the patients. Abnormal tear quality (reduced TBUT) 
was observed in 78% of patients.
Fechtner and colleagues also measured the prevalence 
of OSD in 630 patients from ten clinical sites.6 Their study 
found that 48.4% of the patients had some degree of OSD 
(mild, moderate, or severe). OSD symptom severity was 
positively correlated with the number of topical IOP-lowering 
medications administered. It is evident that the rates of OSD 
are higher for glaucoma patients treated with two or three 
medications than with monotherapy. Unfortunately, patients 
with pre-existing tear dysfunction may be even more suscep-
tible to preservative toxicity.
A large-scale survey of 4107 patients measured the 
incidence of ocular toxicity caused by preservatives in IOP-
lowering medications.7 Eighty-four percent of the patients 
used preserved eyedrops. All ocular symptoms were more 
prevalent in the patients who took preserved topical drops 
compared with those who only received preservative-free 
medications (P , 0.001). These symptoms included dis-
comfort upon instillation, foreign body sensation, dry eye 
sensation, burning-stinging, tearing, and eyelid itching. 
Patients on preserved eyedrops had a more than twofold 
increased incidence of ocular signs. As one might expect, the 
prevalence of ocular signs and symptoms increased with the 
number of preserved drops in the therapeutic regimen.
Another multicenter epidemiologic survey conducted 
in Europe compared the prevalence of side effects between 
preserved and nonpreserved topical beta-blockers for a 
group of nearly 10,000 patients.8 Ocular side effects such 
as foreign body sensation, discomfort upon instillation, 
stinging-burning, and dry eye sensation were significantly 
more frequent in the preserved eyedrops group (P , 0.0001). 
BAK was the most commonly used preservative in topical 
IOP-lowering formulations at that time.9
A large retrospective analysis of over 20,000 patients 
found that glaucoma and ocular hypertension patients 
on a regimen of either latanoprost preserved with BAK 
or   travoprost-Z preserved with SofZia® Preservative 
  System (Alcon Laboratories, Inc, Fort Worth, TX) showed 
no   significant difference in the rates of dry eye, ocular 
  infection, or OSD over a 1-year period. Limitations of this 
claims-based study are its relatively short duration, lack of 
  randomization, and inability to account for sample or over-
the-counter use.10
A large-scale study from Germany, involving 20,506 
patients, sought to analyze the links between glaucoma, dry 
eye, age, medication, and concomitant disease.11 Among indi-
viduals with glaucoma, more women than men were reported 
to develop dry eye (56.9% and 45.7%,   respectively). The dif-
ference in the frequency of dry eye between men and women 
became more obvious after age 50 years.   Hypertension, dia-
betes mellitus, and dry mouth, nose, and skin were the most 
frequent concomitant systemic diseases found in the survey. 
The incidence of dry eye increased with age, the number of 
IOP-lowering medications, and the duration of glaucoma.
The relatively high prevalence of OSD among glau-
coma patients becomes apparent when one compares these 
rates to those in the general population. A cross-sectional 
survey among 25,444 men in the United States found that 
the prevalence of dry eye disease increased with age from 
about 3.9% among men aged 50–54 years to 7.7% among 
those aged $80 years.12 A survey of nearly 40,000 women 
in the United States reported that 5.7% of women ,50 years 
old suffered from dry eye syndrome, compared with 9.8% 
of women $75 years of age.13 These rates are considerably 
lower than those previously mentioned for patients on IOP-
lowering medications.
The effect of preservatives  
on the ocular surface
OSD and inflammation have long been associated with the 
chronic use of IOP-lowering medications and especially the 
preservatives contained in their formulations.7,14,15 A recent 
review suggested that long-term use of topical eyedrops 
can induce a host of ocular surface effects such as ocular 
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discomfort, conjunctival inflammation, subconjunctival 
fibrosis, epithelial apoptosis, tear film instability, corneal 
surface impairment, and the increased risk of failure for 
glaucoma surgery.15
BAK is the most commonly used preservative in topical 
ocular medications.9,15,16 BAK has been shown to remain in 
corneal tissues for an extended period of time. In vivo rab-
bit studies found that BAK was detectable in the cornea and 
conjunctival tissues up to 7 days following instillation of a 
single 30 µL drop.17
BAK is known to disrupt tight junctions in the epithelial 
layer of the cornea.18 Pauly et al conducted studies with a 
human reconstituted corneal epithelial model to measure the 
effect of increasing concentrations (0.001%–0.5%) of BAK 
for 24 hours on the expression and distribution of the tight 
junction protein, occludin.19 BAK caused a disappearance 
of occludin in the superficial layers of the corneal epithelial 
model that was dose dependent.
The effect of BAK on corneal barrier function has been 
assessed by measuring the change in transepithelial electric 
resistance (TER) of rabbit corneas in vivo.20,21 BAK (0.05%) 
caused an immediate decrease in TER.20 Later experiments 
using this model system reported dose-dependent decreases 
in TER upon exposure to concentrations ranging from 
0.02%–0.005%.21 These BAK concentrations are comparable 
to those found in marketed IOP-lowering medications.9,16
Preclinical studies have examined the effect of BAK on 
the ocular surface. Detrimental effects on human conjuncti-
val cell (Wong–Kilbourne derivative of Chang conjunctiva) 
viability and membrane integrity were observed upon expo-
sure to PGA formulations containing BAK.22 In addition, 
apoptosis and necrosis increased upon exposure of the cells 
to BAK. In another set of experiments, growth arrest and 
apoptotic cell death occurred in a dose-dependent manner 
24–72 hours after exposure.23 Debbasch et al, using this 
same conjunctival cell line, found that apoptosis occurred 
at lower concentrations of BAK while necrotic processes 
were observed at higher concentrations of this agent.24 They 
also demonstrated the production of reactive oxygen species 
following exposure of the cells to BAK. Ayaki and Iwasawa 
reported lower cell viability for human conjunctival, rabbit 
corneal, and bovine corneal cells exposed to varying dilutions 
of PGA formulations preserved with BAK.25
Another study showed a decrease in human cor-
neal epithelial cell viability on exposure to a PGA 
topical   formulation containing BAK.26 A dose-dependent 
decrease in cell survival was observed with treatment 
of human corneal and conjunctival cells of increasing 
BAK   concentrations.27 Travoprost with 0.015% BAK was 
shown to have a higher proportion of viable cells compared 
to its vehicle, however. This cytoprotective effect was 
reported by Guenoun and colleagues with both travoprost 
and latanoprost.28 Epstein et al found elevated amounts of 
the inflammatory mediators such as tumor necrosis fac-
tor, C-reactive protein, IL-1, IL-10, and IL-12 in corneal 
and conjunctival epithelial cells exposed to BAK.29 BAK 
at 0.25% and 0.5% appeared to cause a loss of goblet 
cells, increases in corneal thickness, apoptosis, corneal 
  inflammation, and neovascularization in another rat 
  model.30 In addition, Kahook and Noecker reported that 
once-daily administration of latanoprost with 0.02% BAK 
caused a loss of corneal goblet cells in a rabbit model.31
The deleterious effects of BAK have been investigated 
in human clinical trials. Reductions in TBUT were observed 
both 3 hours and 3 days following dosing with BAK-
preserved carteolol.32 Patients who received topical timolol 
preserved with BAK at 0.01% and 0.04% had lower Schirmer 
test values, shorter TBUTs, reduced goblet cell densities, and 
a greater amount of epithelial cell squamous metaplasia when 
compared with healthy age-matched patients in the control 
group.33 Arici and colleagues also observed deleterious 
effects of this preservative on Schirmer and tear break-up 
tests.34 Another clinical study found that chronic dosing of 
timolol maleate, preserved with BAK, caused damage to 
the ocular surface, most notably the mucus layer of the tear 
film.35
Martone et al evaluated the effects of chronic administra-
tion of preserved IOP-lowering medications on the ocular 
surface.36 Patients were divided into six groups based on 
their medication regimen. The preserved medication groups 
showed reductions in Schirmer I scores, esthesiometry, 
TBUT, superficial corneal epithelial cell density, and the 
number of subbasal nerves compared to the normal patients 
and those on preservative-free medications.
Several alternative preservatives have been developed 
in an attempt to minimize the toxic effects of BAK. Purite 
is an oxidative preservative that is used in brimonidine 
topical drops and artificial tears.37 A clinical study with 
brimonidine-purite 0.15% found that the majority of 
  conjunctival hyperemia and allergic conjunctivitis adverse 
events were mild.38
Polyquad® (polyquarternium-1) is a polycationic 
  preservative that is contained in formulations of contact 
lens disinfecting solutions39 and artificial tears.40 Labbe and 
colleagues showed that Polyquad induced considerably less 
toxicity than BAK in vivo.41 Polyquad produced similar 
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results to the control for the tear production test, slit-lamp, 
fluorescein evaluation, and histology.
SofZia, mentioned previously, is a preservation system 
that is contained in the travoprost topical ophthalmic formula-
tion, Travatan Z.16,42 In vitro studies using Chang conjunctival 
cells showed no significant effect on cellular viability and 
membrane integrity.22 No cytotoxicity was observed in cells 
incubated in travoprost with SofZia. Ayaki and Iwasawa 
reported that corneal and conjunctival cells exposed to vary-
ing dilutions (1×, 2×, and 10×) of travoprost preserved with 
SofZia (10, 30, and 60 minutes) had the highest viability of 
any of the PGA formulations tested.25 This formulation also 
did not increase apoptosis or necrosis. Lewis and colleagues 
reported that, during the course of a 3-month study, travo-
prost 0.004% with SofZia was well tolerated in glaucoma 
patients.42 Only one (1/344) patient experienced mild cor-
neal staining. Ocular hyperemia occurred at an incidence of 
6.4%. No treatment-related serious adverse events occurred 
during the study.
Challenges of measuring  
OSD in glaucoma patients
Objective measures
Clinical methods of assessing physiologic functions 
that contribute to ongoing ocular surface health as well 
as   disease have been developed over the past decades. 
Schirmer I (without anesthesia; Schirmer II is performed 
with anesthesia) consists of placing a filter paper strip 
on the lower lid margin in the temporal position of an 
unanesthetized patient.43 This continues to be a useful 
test for the clinician; however, the length of time required 
for the procedure is a disadvantage as it causes discomfort 
to the patient often resulting in reflex tearing which impacts 
the variability of the data.
Several diagnostic tests evaluate the quantity and   quality 
of the tear film. The measurement of TBUT following the 
instillation of a fluorescein dye is a widely used clinical 
technique.44 Nichols et al found the TBUT analysis to be 
more reproducible than the Schirmer test.45 A number of 
factors can reduce the utility of this test in the clinical trial 
setting. These confounding factors can include: heteroge-
neous populations, variations in measurements and scoring, 
concomitant medications, comorbid diseases that affect the 
ocular surface, and environmental differences. If permanent 
damage to the tear-producing cells or glands has occurred, 
then it will be difficult to show any improvement in TBUT, 
regardless of the therapy or preservative. In addition, it is 
known that   fluorescein can destabilize the tear film.46 Efforts 
to minimize these variables, when possible, increase the 
  ability of the TBUT analysis to discriminate between groups 
of varying OSD severity. One study reported that mean TBUT 
improved from 2.02 seconds to 6.34 seconds after a change 
in IOP-lowering therapy from a PGA preserved with BAK 
to one preserved with SofZia (P , 0.001).47
Other methods have been used to measure the clearance 
or turnover of fluorescein instilled into the tears. These 
can include direct fluorometric analysis of fluorescein in 
the precorneal tear film or the inferior tear meniscus. The 
fluorescein clearance test (FCT) was found to be better at 
predicting ocular irritation than the Schirmer I test. The 
FCT also had a higher correlation with meibomian gland 
dysfunction.48 Applying a correction factor from Schirmer I 
to the FCT further improved its correlations with meibomian 
gland dysfunction and ocular irritation symptoms.49
Stains and vital dyes have been used with relatively good 
success in clinical practice. Fluorescein, lissamine green, and 
rose bengal stains, for example, have utility for assessing the 
health of the ocular surface. A number of factors can reduce 
the utility of these tests in the clinical trial setting. These 
confounding factors can include: heterogeneous populations, 
variations in measurements and scoring, and environmental 
influences. These techniques have limitations, as they tend 
to measure the extent of ocular surface damage from dry 
eye and are relatively insensitive in the early stages of dry 
eye disease.
Clinicians often rely on the presence of ocular irritation 
symptoms, the Schirmer test, TBUT, and ocular surface 
vital dyes to diagnose tear dysfunction. More sophisticated 
clinical tests are currently available, which may have greater 
sensitivity for detecting OSD in glaucoma patients, but they 
are currently not widely available. One such technique for 
evaluating the health of the ocular surface (such as dry eye) 
is computerized videokeratoscopy.50–52 This diagnostic tool 
utilizes computer algorithms for analyzing Placido rings 
that reflect off the surface of the cornea. Other noninvasive 
techniques, such as aberrometry,53 have proven to be useful 
for assessing ocular surface health.
Confocal microscopy has been used in recent years 
for evaluating ocular surface health. Using this technique, 
mean individual epithelial cell area and nucleocytoplasmic 
ratios were found to be worse in dry eye patients.54 Benítez-
del-Castillo et al reported that dry eye patients had a reduced 
density of corneal epithelial cells and a decrease in the 
number of subbasal nerves.55 Another study using confocal 
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microscopy reported that the clinical scores were significantly 
lower in the preserved medication group (P , 0.05) compared 
to those for the nonpreserved group. Superficial corneal 
epithelial cell density was reduced in all patients on IOP-
lowering medications (except for the preservative-free group 
[P . 0.05]) compared to control subjects (P , 0.001).
Impression cytology, a method to sample the conjunc-
tival epithelium, has been used to study the underlying 
causes of OSD. The expression of inflammatory markers 
such as HLA-DR was measured in patients taking topical 
IOP-lowering medications using this technique.56 HLA-DR 
was higher in these patients than in either allergic patients 
or normal volunteers.
Sullivan and colleagues recently conducted a prospective 
study of 299 patients across 10 sites in the United States 
and European Union that examined the clinical value of 
tear osmolarity and several other tests for evaluating the 
severity of dry eye disease.57 The rank order of correlation 
coefficients to disease severity, from highest to lowest, was 
osmolarity (r2 = 0.55), conjunctival staining (r2 = 0.47), 
corneal staining (r2 = 0.43), meibomian score (r2 = 0.37), 
TBUT (r2 = 0.30), and Schirmer test (r2 = 0.17). Interestingly, 
disease severity was poorly classified using a combination 
of clinical thresholds for about 63% of patients with mild-
to-moderate dry eye.
Subjective measures
Several survey instruments have been developed for assessing 
ocular surface health. The McMonnies Dry Eye Question-
naire is a subjective method of assessing ocular health from 
the patient’s perspective.58,59 This patient-reported outcome 
instrument was designed to differentiate dry eye patients 
from those with a normal ocular surface.
An OSD-specific questionnaire has been developed 
(OSD-QoL) to evaluate health-related quality of life.60 This 
instrument was developed in France and consists of a diag-
nostic aid and a subjective section that relates to treatment, 
perception of treatment, and quality of life.
The OSDI
Another subjective measurement tool for assessing symp-
toms of OSD is the OSDI.61–63 The instrument consists of 
12   questions that are designed to provide a quick assessment 
of ocular irritation symptoms related to dry eye disease and 
their effect on vision-related functioning.61 The 12 items of 
the OSDI questionnaire are graded on a scale of 0–4 as fol-
lows: 0 = none of the time; 1 = some of the time; 2 = half of 
the time; 3 = most of the time; and 4 = all of the time. The total 
OSDI score is calculated according to the following formula: 
OSDI = ([sum of scores for all questions answered] × 100)/
([total number of questions answered] × 4). The overall OSDI 
score is based on a scale from 0–100, which is defined as fol-
lows: 0–12 = normal; 13–22 = mild OSD; 23–32 = moderate 
OSD; 33–100 = severe OSD.
A factor analysis of the OSDI indicated that there were 
three different subscales within the questionnaire including: 
ocular symptoms, environmental triggers, and vision-related 
function.61 A Cronbach α analysis indicated a high degree of 
internal consistency in all three of the subscales as well as the 
OSDI total score overall. The OSDI scores have been shown 
to correlate with McMonnies questionnaire and the National 
Eye Institute Visual Functioning Questionnaire-25. Some 
differences do exist between these measures due to the fact 
that the OSDI is specific for dry eye disease. This instrument 
was previously validated in a dry eye patient population.61 
To the authors’ knowledge, the OSDI is yet to be validated 
for use specifically with glaucoma patients.
Some investigators have examined the correlation between 
the OSDI and symptoms of dry eye and OSD.   Versura et al 
reported significant correlations between the OSDI subjec-
tive symptoms and tear osmolarity for patients with mild 
(r = 0.313) and moderate (r = 0.462) OSD.64   However, the 
correlation was not significant for patients with severe OSD 
(r = 0.09). Within normal-to-moderate dry eye cohorts, 
Sullivan et al found the following correlation coefficient to 
disease severity: osmolarity (r2 = 0.55), conjunctival staining 
(r2 = 0.47), corneal staining (r2 = 0.43), OSDI (r2 = 0.41), 
meibomian score (r2 = 0.37), TBUT (r2 = 0.30), and Schirmer 
result (r2 = 0.17).57 Valente and colleagues measured the 
signs and symptoms of tear film dysfunction using the OSDI 
in patients on ocular hypotensive drops containing BAK.65 
Approximately half (26/50, 52%) of the patients on an ocular 
hypotensive regimen containing BAK showed symptoms of 
tear film dysfunction. Signs of OSD appeared to be greater 
in patients on more than two topical medications. Signs and 
symptoms of OSD were correlated for patients on mono-
therapy consisting of β-adrenergic antagonists.
Some caveats to consider with the OSDI are the natural 
fluctuations in dry eye symptoms.61 Walker et al found sig-
nificant differences in study participants’ reporting of visual 
function in the OSDI depending on the time of day.66 They 
found more visual function limitations relating to dry eye 
symptoms (eg, working on the computer, driving, watching 
television) in the evening than in the morning.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1579
Challenges measuring ocular surface diseaseClinical Ophthalmology 2011:5
Another factor that may complicate the assessment of 
dry eye using the OSDI is corneal hypoesthesia. Bourcier 
and colleagues have shown that corneal sensitivity tends 
to decrease with age.67 Furthermore, patients with dry eye 
were shown to have higher thresholds for thermal, chemical, 
and mechanical stimulation than their normal counterparts. 
Benítz-del-Castillo confirmed that sensitivity to these stimuli 
was reduced, which was attributed to a decreased number of 
subbasal corneal nerves.55 Martone and colleagues showed 
that the reduction in the number of subbasal nerves was asso-
ciated with a decrease in corneal sensitivity for patients on 
IOP-lowering therapies preserved with BAK.36 This decrease 
in corneal sensitivity may interfere with a patient’s perception 
of dry eye symptoms and therefore confound the interpreta-
tion of results from the OSDI.
Miller and colleagues recently conducted a study with 
310 patients to determine the minimal clinically important 
difference for the OSDI.63 A subject global assessment and a 
clinician global impression served as the basis for estimating 
the minimal clinically important difference for the overall 
OSDI scores (range 0–100). The subject global assessment 
and clinician global impression correlated with the change in 
OSDI score for all categories except for the normal category. 
The range of minimal clinically important difference values 
was 4.5–7.3 for mild and moderate disease, and 7.3–13.4 
for severe disease.
Several confounding factors may cause measurements, 
using the OSDI in large-scale clinical trials that are well 
controlled, randomized parallel groups masked with pro-
spectively-stated statistical objectives, to be problematic. 
The studies often consist of heterogeneous populations 
from disparate study sites. There are individual variations 
in each patient’s response to their dry eye symptoms. 
Concomitant medications or comorbid diseases can also 
affect the ocular surface health. This is particularly true 
of patients with glaucoma, who are usually elderly and on 
multiple chronic topical ocular drops. Longer treatment 
periods are often needed in order to see improvements in 
their ocular surface health. Differences in climate across 
study sites can also affect the outcome. The positive 
placebo effect can confound the evaluation of the patient 
response to treatment. Since the OSDI measures ocular 
surface symptoms, it may not be able to show improve-
ments in OSD per se.
One could expect that the likelihood of showing a differ-
ence for glaucoma patients with the OSDI between treatment 
groups might be higher if certain factors were considered 
in the study design. For example, study patients would 
be on therapy for extended treatment periods. The study 
populations could be limited to mild and moderate dry eye 
patients. No concomitant medications should be allowed. 
The studies could exclude other ocular disease states that 
can affect/  exacerbate OSD. More sensitive parameters such 
as impression cytology could be used. Although difficult to 
incorporate all of these criteria, some study designs have 
attempted to mitigate confounding outcomes.47,68
Clinical results with the OSDI
Several investigators have been able to show differences 
with regard to the ocular surface health of patients with 
glaucoma by using the OSDI. Henry and colleagues con-
ducted a multicenter study using the OSDI with patients 
who changed from their previous prostaglandin therapy to 
travoprost with SofZia.68 Glaucoma and ocular hyperten-
sive patients included in this study were originally taking 
latanoprost or bimatoprost monotherapy and demonstrated 
a need for an alternative therapy due to tolerability issues. 
Overall OSDI scores were 12.0 for latanoprost, 13.2 for 
bimatoprost, and 8.7 for travoprost (after 8 weeks of tra-
voprost treatment; P , 0.0001 vs latanoprost; P , 0.0001 
vs bimatoprost). About 70% of the 253 patients with OSD 
symptoms at baseline had a decrease in symptom severity 
by at least one level (ie, a shift in symptom severity from 
moderate to mild) on the OSDI scale. It was possible to 
discern these differences successfully with the OSDI most 
likely due to the fact that the patients were experiencing 
some adverse effects with respect to tolerability at the 
baseline visit.
Horsley and Kahook evaluated glaucoma patients with 
the OSDI 8 weeks after they made a transition from latano-
prost with 0.02% BAK to travoprost with SofZia.47 Patients 
were required to have a baseline TBUT ,6 seconds and they 
were instructed to avoid using other topical drops during 
the study. At the 8-week time point they found that there 
were decreases in mean inferior corneal staining from 2.40 
to 1.38 (P , 0.001) and mean OSDI scores from 26.31 to 
16.56 (P , 0.001). In this trial, the ability of the OSDI to 
discriminate between the two groups was improved by a 
careful design of the protocol that attempted to minimize 
confounding factors (such as other topical medications).
Katz and colleagues measured the symptoms of OSD in 
patients with ocular hypertension or open-angle glaucoma 
that had been on BAK-preserved latanoprost 0.005% mono-
therapy for at least 1 month.69 The patients had baseline scores 
of $13 on the OSDI. They were then randomly assigned to 
either continue with latanoprost therapy or   transition to 
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travoprost without BAK (preserved with SofZia). OSDI 
evaluations were repeated at 6 and 12 weeks. Mean OSDI 
scores at 12 weeks were significantly lower for patients with 
mild OSD in the travoprost (11.6 ± 10.8) group than in the 
latanoprost (14.4 ± 11.9) group (P = 0.04). Patients who had 
previously been treated with BAK-preserved latanoprost 
for .24 months were more likely to improve to a normal 
OSDI score after 12 weeks if they were transitioned to tra-
voprost preserved without BAK (P = 0.03).
These clinical studies demonstrate, despite aforementioned 
issues with the application of the OSDI to differing patient pop-
ulations and OSDI instrument caveats, that clinically significant 
differences in OSD symptoms can be identified with the OSDI. 
This tool continues to be used in clinical trials in an attempt to 
characterize the effect of different drugs, environmental factors, 
and diseases on the health of the ocular surface.
Conclusion
Due to challenges that clinicians face with both subjective 
and objective ocular surface health assessments, discerning 
clinical improvement in OSD can be a difficult task. Further 
work needs to be done to optimize existing clinical methods 
and/or identify alternative methods for assessing OSD in 
glaucoma patients.
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